Boehringer Ingelheim introduces NexGard SPECTRA® for dogs in India
(This story has not been edited by THE WEEK and is auto-generated from a PTI
Stay updated with breaking news from Human Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(This story has not been edited by THE WEEK and is auto-generated from a PTI
The finding did not reach statistical significance in the primary composite endpoint.
/PRNewswire/ -- Boehringer Ingelheim, the largest animal health company in Georgia, is proud to announce its new partnership with the Atlanta Braves and the...
/CNW/ - For the past six months, inpatients receiving care at Vancouver Coastal Health's (VCH) Vancouver General Hospital have been able to fuel their healing...
Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive symptoms of schizophreniaSosei Heptares will receive EUR 25 million upfront from Boehringer Ingelheim and is eligible for an option exercise payment of EUR 60 million and further milestone payments totaling up to EUR 670 million plus tiered royalties Ingelheim, Germany, Tokyo, Japan and Cambridge, UK,